Corporate News
Market Performance of Citius (CTXR)
During the 24‑hour period ending at 01:24 AM Central Europe on Saturday, 24 November 2026, Citius Pharmaceuticals, Inc. (ticker CTXR) experienced a decline of 6.31 % in its share price. At the close of the trading session, the stock was valued at approximately USD 0.40 on the most actively traded exchanges.
The company’s outstanding share count stands at 27.5 million, giving it a market capitalisation of USD 10.9 million. In the last 24 hours, roughly USD 126.1 k of Citius shares were exchanged. Over the past month, the stock has fallen 34.8 % from its previous closing level, indicating a sustained downtrend.
The 200‑day simple moving average (SMA) for CTXR is USD 0.67, placing the current price well below this long‑term benchmark. The 52‑week high of USD 1.83 was reached on 27 October 2025, while the 52‑week low of USD 0.37 occurred on 22 October 2026, underscoring the volatility that has characterised the stock’s recent performance.
Peer Performance – 24‑Hour Snapshot
| Stock | Ticker | Recent Move | Current Price (USD) | Market Cap (USD) |
|---|---|---|---|---|
| Sintx | SINT | -5.75 % | 1.58 | 12.4 m |
| Netcapital | NCPL | -22.28 % | 1.34 | 12.6 m |
| Sadot | SDOT | +1.21 % | 7.00 | 12.9 m |
| Barnwell Industries | BRN | -2.25 % | 0.87 | 12.9 m |
| Vyome | HIND | -2.17 % | 1.79 | 12.9 m |
These figures illustrate a broader market trend of volatility within the biopharmaceutical and related sectors, with several peers experiencing significant declines while a few, like Sadot (SDOT), posted modest gains.
Company Overview
Citius Pharmaceuticals, Inc. is a late‑stage biopharmaceutical enterprise headquartered in Cranford, New Jersey. The company focuses on a diversified pipeline of anti‑infectives aimed at supporting adjunct cancer care, oncology, stem cell therapy, and other prescription products. As a U.S.‑based firm, Citius is listed on the Nasdaq stock exchange and continues to pursue research and development initiatives that align with its strategic vision of expanding therapeutic options for patients with complex medical needs.
